Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Moderate to Severe Allergic Asthma (Japan)
jRCT2080220140Phase 3
- Sponsor
- Novartis
- Start
- Oct 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of omalizumab in allergic asthma and asthma, sponsored by Novartis.
02
Drugs
omalizumab
03
Conditions
allergic asthmaasthma
Beyond the preview
Go deeper on jRCT2080220140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220140.